Perkasie, Penna. – February 25, 2014 – Secant Medical® has named Dawn Porter Eringis as Vice President, Business Development and Marketing. She was previously Vice President, Commercialization and Scientific Affairs at PolyMedix, Inc., a biotechnology company that she co-founded in 2002. In addition to overseeing the implementation of new business development and marketing programs, Eringis will manage strategic licensing opportunities and academic business partnerships for Secant Medical.

“Dawn’s extensive industry knowledge will play a key role in ensuring that we maintain a forward momentum in our commitment to developing and commercializing advanced biomaterial technology platforms,” said Jeff Robertson, president. “Her leadership will help us continue to build a strong R&D pipeline while also maintaining our focus on business partnerships with clients and academia.”

Eringis has also held positions at Pfizer, Inc., Johnson & Johnson-Merck, Guilford Pharmaceuticals, Inc., the American Red Cross and Locus Pharmaceuticals, Inc. She holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and a Masters in Business Administration from The Wharton School.

About Secant Medical:Secant Medical provides advanced biomaterials and biomedical textile structures to the medical device industry. We partner with clients to design, develop, and manufacture high-performance biomedical structures for applications in cardiovascular, neurovascular, orthopedic and general surgery. Built on a 70-year history, we’re committed to the future of regenerative medicine and actively engage in research partnerships to advance next-generation biomaterial technology into practical applications for the medical device and pharmaceutical industries. Secant Medical is a business unit of Fenner PLC, a worldwide leader in reinforced polymer engineering headquartered in Yorkshire, England. For more information, contact Maria Fontanazza at 215-257-8680 x2192 or [email protected]; or visit

View website